Tag Archive for: PARP1

EvoPAR-PR01: Saruparib (AZD5305) Phase III Trial in Metastatic Castration-Sensitive Prostate Cancer

/in , , /by

Saruparib (AZD5305), a next-generation PARP1-selective inhibitor, represents a promising evolution in prostate cancer therapy, particularly for metastatic castration-sensitive disease (mCSPC), through the ongoing phase III EvoPAR-PR01 trial. Unlike first-generation PARP inhibitors (PARPi) such as olaparib that target both PARP1 and PARP2, saruparib specifically inhibits and traps PARP1 on DNA damage sites, sparing PARP2 to potentially […]

Read more

SPR1020: a Promising PARP1-Selective Inhibitor in Advanced Solid Tumors (Including mCRPC)

/in , , , /by

A  first-in-human Phase 1/2 trial of SPR1020, a highly selective PARP1 inhibitor, dosed its inaugural patient, igniting hope for patients with advanced solid tumors harboring DNA repair deficiencies. This open-label, multicenter study employs a classic 3+3 dose-escalation design to pinpoint the recommended Phase II dose or maximum tolerated dose, transitioning seamlessly into expansion cohorts tailored […]

Read more

ANDROMEDA: Phase 1/2 Trial of AZD9750 AR Degrader in Metastatic Prostate Cancer

/in , , , /by

The ANDROMEDA trial, a first-in-human Phase 1/2 study, is evaluating AZD9750, a novel androgen receptor (AR) PROTAC, in men with metastatic castration-resistant prostate cancer (mCRPC). PROTACs represent a paradigm shift in targeted therapy: unlike traditional AR inhibitors that merely block the receptor’s activity, AZD9750 recruits cellular machinery to completely degrade the AR protein, potentially overcoming […]

Read more